Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million

Company Overview - Relay Therapeutics is a clinical-stage biotechnology company focused on precision medicines for oncology and genetic diseases, utilizing advanced computational modeling and partnerships to develop small-molecule therapies targeting key disease pathways [5] - The company has a market capitalization of $1.9 billion and reported a revenue of $8.36 million for the trailing twelve months (TTM), with a net income loss of $297.59 million [4] Recent Developments - On February 17, 2026, Casdin Capital disclosed an increase in its holding of Relay Therapeutics by 1,662,193 shares, raising its total to 13,003,574 shares, with an estimated transaction value of $11.86 million [2][6] - The quarter-end value of Casdin's position in Relay increased by $50.81 million, reflecting both additional purchases and stock price movements [2] Financial Position - Relay Therapeutics ended 2025 with approximately $555 million in cash, cash equivalents, and investments, which is expected to fund operations into 2029 [10] - The company reported a full-year net loss of $276.5 million, with elevated research spending [10] Stock Performance - As of the last reported price, Relay shares were valued at $10.95, representing a 235% increase over the past year, significantly outperforming the S&P 500's approximately 15% gain during the same period [6] Pipeline and Future Prospects - Relay is advancing several lead candidates, including RLY-4008, RLY-2608, and RLY-1971, and is focused on small molecule therapeutics for targeted oncology and genetic diseases [7] - The company anticipates multiple data disclosures in 2026, including Phase 1 data related to PIK3CA-driven vascular anomalies and updates on breast cancer triplet strategies involving its lead asset, zovegalisib, which is currently in a Phase 3 trial for HR positive, HER2 negative metastatic breast cancer [9]